Is Wall Street Bullish or Bearish on Cardinal Health Stock?

Barchart
Öffnen unter Barchart
Is Wall Street Bullish or Bearish on Cardinal Health Stock?

Based in Dublin, Ohio, Cardinal Health, Inc. (CAH) is a global healthcare services and products company. It distributes pharmaceuticals and specialty products, supplies medical and laboratory equipment, provides home healthcare services and logistics, and operates nuclear pharmacies and manufacturing facilities, serving healthcare providers and patients worldwide. The company has a market capitalization of $65 billion.

Shares of this healthcare services giant have substantially outperformed the broader market over the past year. CAH has gained 36.4% during this period, while the broader S&P 500 Index ($SPX) has gained nearly 12.2%. Likewise, the stock is up 36.8% year-to-date, surpassing the index's 10.5% gain over the same period.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Narrowing the comparison, CAH has also outpaced the State Street Health Care Select Sector SPDR ETF (XLV), which has risen 23.6% over the past year and 22% year-to-date.

www.barchart.com

On Nov. 5, 2026, Cardinal Health reported first-quarter fiscal 2027 results, beating analyst estimates for both revenue and adjusted earnings, with shares rising approximately 2.3%. Revenue increased 5.5% year over year to $67.5 billion, while non-GAAP diluted EPS climbed 27.8% to $3.26. Non-GAAP operating earnings rose 16.7% to $1 billion. Pharmaceutical and Specialty Solutions revenue increased 5.7% to $62.6 billion, driven by brand and specialty pharmaceutical sales and positive generics program performance. Meanwhile, Global Medical Products and Distribution revenue remained essentially flat at $3.2 billion.

Following the results, Cardinal Health raised its fiscal 2027 non-GAAP diluted EPS guidance to $12.80 to $13 from $12.40 to $12.60, reflecting expected growth of 17% to 19% against its adjusted fiscal 2026 baseline. It also increased its Pharmaceutical and Specialty Solutions segment profit growth outlook to 10% to 12% from 8% to 11%, and its Other segment profit growth forecast to 17% to 20% from 15% to 18%. During the quarter, the company completed a $500 million share repurchase program and entered into a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health.

On Nov. 11, 2026, Cardinal Health approved a quarterly dividend of $0.52 per share, payable Jan. 15, 2027, to shareholders of record as of Jan. 4, 2027, continuing its capital returns to shareholders.

For the current fiscal year, ending in June 2027, analysts expect CAH’s diluted EPS to rise by 15.2% to $12.97. Notably, the company has also surpassed Wall Street’s consensus EPS estimates in each of the past four quarters.

Among the 17 analysts covering CAH stock, the consensus rating is “Strong Buy.” This rating is based on 13 “Strong Buy,” one “Moderate Buy,” and three “Hold” recommendations.

www.barchart.com

The configuration is more bullish than it was three months ago, when the stock had 14 “Strong Buy” recommendations.

On Nov. 12, 2026, Argus Research analyst Steven Silver maintained a “Buy” rating on Cardinal Health and raised the price target from $264 to $309. 

The mean analyst price target of $293.69 implies a 4.5% premium to CAH's current share price, while the Street-high target of $320 suggests a potential premium of 13.8%.


On the date of publication, Abhishek Bhuyan did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

How to Invest Like a Cockroach in the Stock Market’s AI Era Why It’s Time to Load Up on CoreWeave Stock Dear AST SpaceMobile Stock Fans, Mark Your Calendars for November 17 Who Is Ian Buck? 10 Things to Know About the Nvidia Executive Investors Are Betting on to Replace Jensen Huang.